STOCK TITAN

Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host its first-ever Strategy Day on Thursday, February 2nd, 2023, at the Nasdaq MarketSite in New York City, starting at 1:30 PM ET. The event will include presentations from members of the company's leadership team and panel discussions featuring key opinion leaders in basic and clinical research areas including cancer, genetic disorders and cell bioprocessing. Bionano panel members will also participate in a Q&A discussion with the audience.

The event will include a live webcast which will be archived and available for replay after the event. Please visit the "Investors" section of the company website at https://ir.bionanogenomics.com/ to register for the webcast and for additional information on the event.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

For more information, visit www.bionanogenomics.comwww.bionanolaboratories.com or www.biodiscovery.com

CONTACTS

Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com

Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com


Bionano Genomics, Inc.

NASDAQ:BNGO

BNGO Rankings

BNGO Latest News

BNGO Stock Data

61.02M
54.49M
0.5%
11.91%
9.64%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
SAN DIEGO

About BNGO

at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o